ACADIA Pharmaceuticals Inc at JMP Securities CNS Forum (Virtual) Transcript
Great. Well, thank you, everybody, again for joining us today for the JMP Securities CNS Forum. Really excited to have ACADIA with us next, both Steve Davis, the company's CEO; and Michael Yang, Chief Commercial Officer. Another great first half of the year for NUPLAZID and the on-label indication of Parkinson's disease dementia -- sorry, psychosis. And obviously, a lot of progress with the dementia-related psychosis indication, which you've now submitted the sNDA for.
So maybe -- again, let's just turn it over to you, Steve, for any additional introductory comments, but then would love to just jump in and review how you think the first half of the year went and how you're positioned commercially for the second half of the year with NUPLAZID.
Great. Perfect. Thanks much, Jason. So maybe just to level set, I'll offer a few very brief remarks, and then we'll
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
